Journal of oncology research and therapy最新文献

{"title":"Pregnancy Outcome from an Oocyte Retrieval Following Chemotherapy for Breast Cancer","authors":"M. B. Dratver, E. Ginsburg, A. Lanes, C. Gordon","doi":"10.29011/2574-710x.10130","DOIUrl":"https://doi.org/10.29011/2574-710x.10130","url":null,"abstract":"As mortality rates for reproductive age cancer patients improve, it is vital to understand how treatments such as chemotherapy reduce reproductive potential. Fertility preservation before gonadotoxic chemotherapy initiation is not always possible when treatment must start as soon as possible. There are minimal data regarding pregnancy in patients who have undergone fertility preservation after chemotherapy and subsequently delivered from cryopreserved embryos. Here we report two cases of patients with breast cancer who underwent ovarian hyperstimulation and embryo cryopreservation within 12 months of chemotherapy. The first patient was diagnosed with triple negative invasive ductal carcinoma and underwent oocyte retrieval 6 months after her last dose of chemotherapy. Via gestational carrier, a term healthy infant was born. The second patient was diagnosed with hormone receptor negative, HER-2 positive invasive ductal carcinoma and underwent oocyte retrieval 2 months after her last dose of chemotherapy. Her frozen embryo transfer did not result in pregnancy. To our knowledge, this is the first report on embryo transfer outcomes in women with breast cancer using embryos cryopreserved within a year of chemotherapy exposure.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84405804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Ismail’s Guide wheel on the Management of Less Common Ovarian Cancers","authors":"M. Ismail, F. Ismail, Julia Ismail, Muneera, Alkhalifa, Rehab Ismael, Reham Fathi, Wassan Al Ani, Shaikha Al, Hajri, Nada Abduljawad, Nawal Saad AlAbdullah, Sabeeka Alaujan, Y. Hussain, Gulmeen Raza, Mariam Fida, Alaa Zeineldine, Uwe, Torsten, E. Fadel","doi":"10.29011/2574-710x.010129","DOIUrl":"https://doi.org/10.29011/2574-710x.010129","url":null,"abstract":"We developed Ismail’s Guide wheel on the Management of Less Common Ovarian Cancers as an extension to Ismail’s Guide wheel on the Management of Epithelial Ovarian Cancer Including Fallopian Tube and Primary Peritoneal Cancer. The former mainly discusses the adjuvant therapy for patients with less common epithelial ovarian cancer such as clear-cell carcinoma and mucinous carcinoma along with non-epithelial OC such as malignant sex cord-stromal tumors, malignant germ cell tumors and carcinosarcomas while the latter also discusses the primary therapy for those types of tumors. This guide wheel comprises of an amalgamation of the recommendations by international health organizations including the National Comprehensive Cancer Network (NCCN), the Society of Gynecologic Oncology (SGO), the British Gynecological Cancer Society (BGCS), the National Institute of Care and Excellence (NICE), the Royal College of Obstetricians and Gynecologists (RCOG), the European Society of Gynecological Oncology (ESGO), the European Society for Medical Oncology (ESMO), the Korean Society of Gynecologic Oncology (KSGO), the Spanish Society of Medical Oncology (SEOM), the Society of Obstetricians and Gynecologists of Canada (SOGC) and the International Federation of Gynecology and Obstetrics (FIGO). Ismail’s Guide wheel on the Management of Less Common Ovarian Cancers serves as a quick, feasible reference for physicians when counseling patients diagnosed with those less common ovarian cancers regarding the expected course of treatment bearing in mind the significance of individualizing treatment to each patient’s unique case.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78205157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Older Breast Cancer: Not all T1 HR+ Breast Cancers are Equal","authors":"","doi":"10.29011/2574-710x.10127","DOIUrl":"https://doi.org/10.29011/2574-710x.10127","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74677685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Ismail’s Guide Wheel on the Management of Epithelial Ovarian Cancer Including Fallopian Tube and Primary Peritoneal Cancer","authors":"M. Ismail, F. Ismail, Julia Ismail, Muneera, Alkhalifa, Rehab Ismael, Reham Fathi, Wassan Al Ani, Shaikha Al, Hajri, Nawal Saad Alabdulla, Nada Abduljawad, Nusiba Ibrahim, Elhassan, Aysha Alyasi, Gulmeen, Raza, Mariam, Fida, Alaa, Zeineldine, E. Fadel, U. Torsten","doi":"10.29011/2574-710x.010128","DOIUrl":"https://doi.org/10.29011/2574-710x.010128","url":null,"abstract":"Development of Ismail’s Guide Wheel on the Management of Epithelial Ovarian Cancer Including Fallopian Abstract We designed Ismail’s Guidewheel on the Management of Epithelial Ovarian Cancer Including Fallopian Tube and Primary Peritoneal Cancer to help guide physicians through a standardized approach to the primary and adjuvant therapy for patients diagnosed with those conditions along with surveillance and the management of recurrent disease. We amalgamated recommendations from international health organizations on a wheel, which can easily be used during a consultation with a patient to provide a simplified yet comprehensive approach to their management. We included recommendations by the following organizations: the National Comprehensive Cancer Network (NCCN), the American College of Obstetricians and Gynecologists, the American Society of Clinical Oncology (ASCO), the Society of Gynecologic Oncology (SGO), the British Gynecological Cancer Society (BGCS), the National Institute of Care and Excellence (NICE), the Royal College of Obstetricians and Gynaecologists (RCOG), the Scottish Intercollegiate Guidelines Network (SIGN), the European Society of Gynaecological Oncology (ESGO), the European Society for Medical Oncology (ESMO), the Korean Society of Gynecologic Oncology (KSGO), the Spanish Society of Medical Oncology (SEOM), the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the International Federation of Gynecology and Obstetrics (FIGO). This wheel is meant to be a quick and accessible resource for physicians but is not intended to replace alogorithms set by the aforementioned organizations.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87184010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Useful are 3-monthly MRI Surveillance Scans after Stereotactic Radiosurgery for Brain Metastases? A Single Institution Experience","authors":"","doi":"10.29011/2574-710x.10125","DOIUrl":"https://doi.org/10.29011/2574-710x.10125","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89151537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Older Breast Cancer in Australia: Tumour Characteristics of Screened Versus Symptomatic Breast Cancers","authors":"Dr Adam Ofri, N. Bhimani, Dr Sanjay Warrier","doi":"10.29011/2574-710x.10126","DOIUrl":"https://doi.org/10.29011/2574-710x.10126","url":null,"abstract":"Background: Breast cancer is the most common non-skin cancer in Australia, affecting 1 in 7 women by the age of 85. The Australian 2020 projected incidence of breast cancer in the older population, 70 years or greater, is over 6500. This is almost a third of the entire projected incidence of over 20,000. BreastScreen Australia invites women aged 50-74 years of age for biennial screening; however, a significant proportion of Australian women continue screening well beyond this. We have evaluated the tumour characteristics of older breast cancer patients - comparing symptomatic to screen detected patients. Methods: This was a retrospective study of data from the BreastSurgANZ Quality Audit (BQA) between 1 January 2001 and 31 December 2019. Female patients aged ≥ 70 at diagnosis were included only. Exclusion occurred for incompletely recorded cases. Patients were then divided based on means of detection - either screen detected (Group A) or symptomatic (Group B). Results: From 1 January 2001 to 31 December 2019, 34,258 patients were appropriately reported in the BQA. There were 11,021 in Group A and 23,237 in Group B. DCIS was more prevalent in Group A (16.83% versus 6.49%, p = <.001). T stage distribution was statistically different, with higher T stages for Group B, p = <.001. IDC sub-type distribution varied between the two groups, p = <.001. IDC Grade 3 and lymphovascular invasion were more common in Group B (p = <.001). Hormonal status was statistically different, with Group B having greater rates of TNBC and HER2+ cancers compared to Group A (12.99% versus 7.10%, p = <.001 and 4.45% versus 2.55%; respectively, p = <.001). Conclusion: This is the first BQA review of older breast cancer tumour characteristics, comparing screen to symptomatic patients. As hypothesized, screen detected cancers were smaller and earlier stage, compared to symptomatic patients. Tumour biology was statistically less favourable in Group B being higher grade, and greater rates of lymphovascular invasion, TNBC and HER2+ cancers.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80973401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the G8 Screening Tool in Older Patients with Cancer: A Retrospective Analysis","authors":"M. Schlögl, D. Blum, E. Schmidt, -. FranziscaDomeisen, Benedetti, F. Strasser","doi":"10.29011/2574-710x.10124","DOIUrl":"https://doi.org/10.29011/2574-710x.10124","url":null,"abstract":"Aim: The aims of this study were to evaluate the results of the Geriatric 8 (G8) screening in patients aged 75 years and over. Findings: Of 2,294 patients screened, 177 were ≥ 75 years. 120 patients (68%) were vulnerable as defined by a G8 score ≤ 14. Vulnerable patients showed worse outcomes than fit patients did. In binary logistic regression modeling, the G8 domains of nutritional intake and health status were predictive of hospitalization and of death, when controlling for all other variables. Message: The G8 screening is applicable and can discriminate between fit and vulnerable patients in oncology. Prospective use in treatment decisions might improve care for geriatric cancer patients. Abstract Purpose: To evaluate the results of the Geriatric 8 (G8) screening in patients aged 75 years and over. Methods: In this retrospective single-center study, we screened the medical records of 2294 patients referred to the Department for Medical Oncology in St. Gallen, a tertiary hospital in Switzerland, over a period of 29 days. For each patient aged 75 and older, the responsible oncologist completed the G8 questionnaire. The cohort was followed to obtain data on patient outcomes for the 4 months following the completion of the G8 assessment. Patients’ charts were reviewed following a standardized approach. Information regarding given anticancer treatment, anticancer toxicity, date and reason for inpatient admission, date of inpatient discharge, and date of death was documented. Data were analyzed using the Χ 2 test and binary logistic regression. Results: Of 2,294 patients screened, 177 were ≥75 years. 176 G8 assessments were completed on patients with various tumor types. 152 (86%) were outpatients and 112 (64%) males. Mean age was 79.9 years (SD 4.3). 120 patients (68%) were vulnerable as defined by a G8 score ≤ 14. Vulnerable patients showed worse outcomes than fit patients did. In binary logistic regression modeling, the G8 domains of nutritional intake and health status were predictive of hospitalization and of death, when controlling for all other variables. Conclusion: The G8 screening is applicable and can discriminate between fit and vulnerable patients in oncology. Prospective use in treatment decisions might improve care for geriatric cancer patients.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77106495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Antiangiogenic Agent Associated with Multi-Targets Exhibits Synergistic Antitumor Effects in Combination with Immunotherapeutics","authors":"Liting Xue, Kun Wang, Xinxin Li, Janine Yang, Wenjie Song, R. Tang, Wen-qing Yang","doi":"10.29011/2574-710x.10123","DOIUrl":"https://doi.org/10.29011/2574-710x.10123","url":null,"abstract":"Recently, an increasing number of studies have focused on the combination of antiangiogenic agents and Immune Checkpoint Inhibitors (ICIs) in preclinical and clinical settings. In this commentary, we discuss the combination of recombinant human endostatin (Endostar, Simcere) with immunotherapy. Similar to the anti-vascular endothelial growth factor (VEGF) antibody BD0801, Endostar is an antiangiogenic agent with VEGF binding affinity. In addition, Endostar binds to basic Fibroblast Growth Factor (bFGF) and blocks the binding of bFGF to FGF receptor 1 (FGFR1). Endostar in combination with anti-PD-L1 antibody showed synergistic antitumor effects in both colorectal cancer and melanoma mouse models. Furthermore, VEGF concentrations in the serum of tumor-bearing mice were significantly decreased upon Endostar and combination treatments. Significantly, increased CD8+ T cell infiltration and reduced Microvessel Density (MVD) in tumors were observed in the combination group. In conclusion, Endostar exerted a synergistic antitumor effect with immunotherapy, revealing a mechanism of synergy in the combination of antiangiogenic agents and immunotherapy involving tumor microenvironment modulation.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85790985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cigarette Smoke Extract induces Alpha-Enolase by inhibiting Prolyl-Hydroxylases in Cervical Cancer Cells. A comparative study of Reference cigarettes and E-cigarettes","authors":"Surya Singh, Divya J. Reddy, R. Eslavath, Wasia Rizwani","doi":"10.29011/2574-710x.10120","DOIUrl":"https://doi.org/10.29011/2574-710x.10120","url":null,"abstract":"Cigarette Smoke (CS) is a major contributor to the development of a large number of fatal and debilitating disorders. Proteomic analysis was used as an investigative tool to systematically explore proteomic changes that contribute to alterations in the cellular milieu leading to progression of cancer upon CS exposure. In this study, we utilized Two-Dimensional Gel Electrophoresis (2-DE) and Mass Spectrometry (MS) technologies to explore protein changes in cervical cancer cells (HeLa) in response to cigarette smoke extract (CSE) exposure. Among the individual proteins resolved using 2DE, about 50 protein spots were analysed by MALDI-TOF/TOF in the first attempt. Proteins related to tumor microenvironment, chronic obstructive pulmonary disease and metastasis induction among others were identified. Of these, alpha-enolase, a multi-functional, yet predominantly a glycolytic enzyme that facilitates aerobic glycolysis through a process known as Warburg effect in cancers, was a prominent protein detected with significant change. Although this protein is known to be induced in cancers, it was not known to be altered by cigarette smoke exposure in cervical cancers. Mechanism-wise CSE induced and stabilized HIF-1a by inhibiting HIF-PH (prolyl-hydroxylases) and thereby, inducing alpha-enolase production in cervical cancer cells. The precise molecular mechanisms underlying the effects of CS in cervical disease are largely unknown. Further investigation on CSE treatment under non-hypoxia conditions in vitro and in vivo along with proteomic approach may potentially lead to new therapeutic approaches to smoking induced advancement of cervical cancer. The evidence warrants further investigation to indicate that Enolases play an important role in CS-induced gene expression and could be a potential therapeutic target to prevent cancer progression and metastasis.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"49 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72393168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Colon Cancer Succeeding Long Survival Without Chemotherapy, Msi-H, Braf Mutated","authors":"Maria-Theodora Papadimitriou, D. Symeonidis, Alexandros-Nikolaos, Liatsos, S. Xynogalos","doi":"10.29011/2574-710x.010119","DOIUrl":"https://doi.org/10.29011/2574-710x.010119","url":null,"abstract":"Immunotherapy is now indicated in the first line setting in metastatic colon cancer, while it is generally indicated in MSI-H tumors. A similar BRAFm V600E mutation is a poor prognostic indicator, while there is approved treatment in the 2nd line. The tolerance profile of these treatments may be the same or even better compared to chemotherapy and their use has gained considerable priority. The aim with this report is to highlight the possibility of successfully treating a patient with metastatic colon cancer without chemotherapy in the first two lines, especially when it ought to a frail patient. The patient is monitored in our department from the beginning of her diagnosis until the moment of this publication.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78335921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}